AstraZeneca
Global Clinical Program Lead – Neuroimmunology, Immunology, BioPharmaceuticals R&D
$288K–$432K
US - Cambridge Kendall SQ - MA · Full-time · Posted Oct 30, 2026
- Experience
- At least 5 years of biopharmaceutical clinical drug-development experience.
- Education
- MD or equivalent degree from an accredited university, or MD (or equivalent) plus a PhD; postgraduate specialty training and board certification in neurology or a related immune-mediated disease specialty.
About the job
Leads clinical strategy, safety, study delivery, and regulatory engagement for two neuroimmunology development programs spanning multiple sclerosis and neuromuscular disease.
What you'll do
- Own benefit/risk, clinical strategy, development plans, and clinical content for regulatory submissions.
- Lead study design and delivery, program safety oversight, and health-authority interactions.
- Guide cross-functional teams and represent programs with internal governance, external experts, investigators, and patient partners.
What they ask for
- MD or equivalent degree from an accredited university, or MD (or equivalent) plus a PhD.
- Postgraduate specialty training and board certification in neurology or a related immune-mediated disease specialty, with substantive attending- or consultant-level clinical experience.
- At least 5 years of biopharmaceutical clinical drug-development experience, including leadership of a clinical program or major studies through key milestones.
- Experience leading health-authority interactions and contributing clinical content to regulatory submissions; command of FDA, EMA, MHRA, and ICH GCP requirements.
Nice to have
- Clinical-development experience in neuroimmunology or neuromuscular disease, including relevant external relationships.
- Clinical-development experience with immune-reset therapies in autoimmune indications; familiarity with the CMC-clinical interface or clinical/commercial interface.
Pay
288,059.20 - 432,088.80 USD Annual (base salary)
Tools
FDA, EMA, MHRA, ICH GCP, IND, CTA, CMC
Model-written summary · the original posting is authoritative